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LETTER TO THE EDITOR 
8-Methoxypsoralen Levels In Blood 
To the Editor: 
We read with interest the article by Chakrabarti et al [1) and have 
some remarks about the results and conclusions presented in this 
paper. 
At the end of the article the authors conclude. " Since our results 
appear to be higher than those reported elsewhere, we believe 
that the reverse-phase HPLC method is more sensitive . .. ". In 
our opinion, higher sensitivity does not explain high 8-meth-
oxypsoralen (8-MOP) concentrations. We also do not agree with 
the opinion that the reverse-phase high-performance liquid chro-
matography (HPLC) method is more sensitive than other analytic 
methods (e.g., the straight-phase HPLC method) that are in-
cluded in the reference list of Dr. Chakrabarti's article [1]. The 
difference between the 2 methods lies in the principle of sepa-
ration. Sensitivity, on the other hand, depends on the detection 
method used , which is UV -detection both with straight- and 
reverse-phase HPLC. Numerous reverse-phase HPLC methods 
fo r determination of 8-MOP in body fluids were recently re-
ported in the literature [2-4]. but none of them have been referred 
to in the article. 
We were astonished by the unusually high blood concentrations 
p resented in this paper-peak levels ranging from 130-3892 ng/ml. 
The phannacokinetic behavior of 8-MOP seems rather peculiar; 
e.g . , the 8-MOP concentration of 3892 ng/ ml after 2 h and of 
490 ng/ml after 3 h , indicating a half-life for elimination of about 
20 minutes! According to recent review articles [5 ,6] on clinical 
pharmacokinetics of8-MOP, the mean maximum serum or plasma 
concentrations are about 200 ng/ml (range 0-500 ng/ ml) and the 
half-life for elimination is about 1 h. Blood concentrations are 
67% of plasma or serum concentrations [7]. 
We also have some remarks about the assay of 8-MOP de-
scribed in this article. The exact composition of the mobile phase 
is not indicated. The sensitivity of the detector (0.1 A UFS) is 
ins ufficient for measurement of the 8-MOP standard curve 
(2 .0-20.0 ng) . The standard deviations of the peak heights of the 
s tandard curve are enormous (ranging from 17-23%) . The stan-
dard curve is not composed of spiked blood samples and covers 
the range from 2-20.0 ng per injection (equivalent to 20-100 
ng/ml blood), whereas most 8-MOP concentrations in patients 
are much higher than 100 ng/ml. Recovery studies have been 
done with 8-MOP concentrations ranging only from 5-30 ng/ ml 
blood. Our conclusion is that we cannot explain the unusually 
high 8-MOP concentrations with the incomplete assay data pre-
sented. 
Leo M. Stolk, Ph.D. 
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REPLY 
In response to the Letter to the Editor from Drs . Stolk, Siddiqui, 
and Cormane, we would like to clarify the issues that they have 
addressed in our paper (1 J. 
There seems to be a misunderstanding about our conclusions, 
as interpreted by them, in their opinion that "higher sensitivity 
does not explain higher 8-MOP concentrations." Our conclu-
sions clearly stated that "8-MOP is absorbed in the blood un-
evenly and varied from patient to patient. The fact that only 
50-60% of the patients with vitiligo responded to PUV A therapy 
may be related to the variation of absorption of the drug in in-
dividual patients. " We certainly maintain that some of our results 
are higher than reported by other investigators . Our vitiligo pa-
tient population consists primarily of nonwhite subjects. Other 
investigators primarily reported about white patients suffering 
from severe psoriasis [2-21]. Moreover, using the isotopic method, 
Murata and colleagues demonstrated that in rat blood trime-
thylpsoralen levels were in the order of 4000 ng/ ml [22] . Since 
the isotopic method is significantly more sensitive, our results 
may not be out of line [23-25]_ 
Since there are numerous factors that determine the extraction 
of the drug from the blood, sensitivity is only one of the factors. 
We believe that the reverse-phase high-performance liquid chro-
matography (HPLC) method is more sensitive compared with 
gas chromatographic, quantitative thin-layer chromatography 
(TLC) , 'normal-phase HPLC, and even earlier reverse-phase HPLC 
methods, since these methods could measure only 5-10 ng quan-
tities of the drug [26] . By using the reverse-phase HPLC, we can 
measure as little as 2 ng of 8-MOP with 80-90% confidence. 
Drs. de Wolff and Thomas reviewed many methods for psoralen 
assay. They mentioned that "Reverse-phase high performance 
liquid chromatography is the method of choice for determining 
methoxsalen concentrations in body fluids, but gas chromatog-
raphy with electron capture detection and thin-layer chromatog-
raphy with fluorescence detection also give favorable results." 
[26] Our results certainly are consistent with these remarks. . 
Dr. Stolk et al complained that we did not refer to certall1 
articles about reverse-phase HPLC. We would like to remind Dr. 
Stolk and colleagues that we never attempted to provide an alI-
inclusive citation; however, we did not intend to offend anyone. 
We also would like to draw the attention of Dr. Stolk et al the 
fact that we developed the original quantitative thin-layer chro-
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matographic method with fluo rescen ce detection referred to in 
the article by Drs . de Wolff and Thomas [26), and our reverse-
phase HPLC method was reported as early as 1980 [24,25]. 
Dr. Stolk et al were astonished to see our "unusuall y hig h blood 
concentrations ... ". However, they did not care to rook at the 
earlier data reported by Murata et al using the isotopic method 
[22]. 
'With regard to the pharmacokinetic peculiarity of8-MOP, we 
feel, as stated above, that it is indeed peculiar. 
The composition of mobile phase h as been reported previously 
by us [24,25]. About the sensitivity set up, etc., we found that 
the finer the sensi tivity set up, the higher the noise level. About 
the standard curve determination from spiked blood samples, 
these are clearly mentioned in our article and we quote, "enough 
8-MOP was added to 2 .0 ml of blood samples so that the final 
concentrations in blood were 2, 5, 10, 20 and 30 ng/ml. The drug 
was then extracted from each sample as outlined in the assay 
method . .. The amounts of8-MOP added to and recovered from 
blood varied from 83 to 95% . When 5 ng were added per ml of 
blood, 4.15 ± 0 .6 ng (83%) were recovered. Similarly, for 10 
ng, 15 ng and 20 ng 8-MOP added per ml of blood, the respective 
recoveries were 9.10 ± .05 (91%),14.25 ± 0.9 (95%) and 17.20 
± 2.0 (86%) ." Therefore, our assay data is by no means incom-
plete. 
Our findings of unusual high 8-MOP concentrations in blood 
is consistent with the values reported by others. 
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